Optigenex Inc. says a human trial involving healthy adults found statistically significant improvements in attention, memory, executive function and social cognition after daily intake of ac-11®. According to the company these results emerge from a randomized, double-blind, placebo-controlled, cross-over study conducted by the University of Northern Arizona.
In the study design, participants first underwent baseline neuropsychological assessment to confirm normal cognitive function. One group then took ac-11® (350 mg twice daily for 30 days), followed by a 30-day washout, then 30 days of placebo. The second group received the treatments in reverse order. The assessments were repeated after each phase, the company claims.
After treatment with ac-11®, subjects showed statistically significant improvements (p < .05) in focus and attention, as well as memory and executive function, versus placebo. Some 64 percent of participants also showed improvement in social cognition, the company said. The effects were observed across demographic groups, and reportedly persisted into follow-up after cessation of ac-11®.
Optigenex notes that ac-11® (also known as CMED-100®), a patented bioactive ingredient derived from Uncaria tomentosa, is promoted among its dietary supplements. The company emphasized that the study was among individuals with normal cognition, and suggested potential for cognitive enhancement.
